First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Healthy Volunteer, Atopic Dermatitis
In brief
This study will test a study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B). REGN20423 is a study medicine that is only used in clinical studies. REGN20423 has not previously been studied in humans. The study is looking at: * What side effects REGN20423 might cause * How much REGN20423 is in the blood at different times * How well REGN20423 works in adults with atopic dermatitis * Whether the body makes antibodies against REGN20423 * How the body changes after having REGN20423, which can help researchers understand why REGN20423 works better in some people than others * What the best dose of REGN20423 is
Key facts
- Study ID
- NCT07527923
- Run by
- Regeneron Pharmaceuticals
- People needed
- 144
- Starts
- 2026-05-22
- Expected to finish
- 2028-06-23
- Last updated by the study team
- 2026-06-25
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Center for Clinical Pharmacology University Hospitals Leuven (UZ Leuven) — Leuven, Vlaams-Brabant, Belgium (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.